In this Q&A, MMIT's Andrew Rouff shares insights on payer reactions to drug shortages, the proposed Medicare drug shortage prevention program, and how pharma companies can anticipate utilization. https://ow.ly/5PWN50SrfEw
MMIT (Managed Markets Insight & Technology)’s Post
More Relevant Posts
-
Fierce Pharma's latest report unveils the anticipated pharmaceutical shifts of 2024. Delve into the impending generics and biosimilars competition facing industry leaders. From industry giants to niche players, discover the impending transformations shaping the healthcare landscape. #KrugAssociates #PatentExpirations #HealthcareTrends #PharmaInsights #HealthcareShifts
To view or add a comment, sign in
-
The 340B Drug Pricing Program’s rapid growth has created a complex web of financial and legislative challenges for pharma companies. Ricky Yuen and Nick Porter check in on how pharma and states are responding to the program as it changes. https://bit.ly/3KG2LmT #healthcare #pharma #drugpricing
To view or add a comment, sign in
-
The 340B Drug Pricing Program’s rapid growth has created a complex web of financial and legislative challenges for pharma companies. Ricky Yuen, Nicholas Porter, Neelabh Saxena, Harshil Gagnani, and Shreya Bhatia dive into pharma’s and states’ responses to the program’s evolution and the effectiveness of these strategies. Download the white paper to find out how pharma can adapt. #healthcare #pharma #340B #drugpricing #publicpolicy https://lnkd.in/eEcJVKGY
To view or add a comment, sign in
-
Look for increasing market gains, and profit margin strains on existing new generation weight loss/cross-over drugs. The days of increasing prices indiscriminately annually are likely gone (while product costs dynamics either stay consistent, or rise). In addition, new offerings (currently under FDA vetting), will be landing in the market for CY24. #weightlosscommunity #pharma #healthawareness
To view or add a comment, sign in
-
The USA Edition of the 2023/4 Corporate Reputation of Pharma report is now available! This report is based on the feedback of 314 respondent US patient groups across 38 different therapy areas, providing valuable insights on how pharma companies can improve. Click here to read the press release 🔗 https://ow.ly/YvC750Rqcai #patientview #patientcare #pharma #patientadvocacy
To view or add a comment, sign in
-
🚀 Pharma Execs Alert! 🚀 Time's relentless march means one thing for pharma execs: the urgency of new launches to offset revenue lost to the patent cliff. Consider Humira, a global sales titan peaking at over $21 billion. Despite its success, it faced biosimilars in 2023, leading to a sharp decline. At Fierce Pharma, we've compiled the top drugs set to face this fate in 2024. From Bristol Myers Squibb to Novartis, these blockbusters are on the radar. Navigating legal and regulatory uncertainties, our report uses a mix of company filings and outside sources for reliability. Get ahead with insights from Corporate Pharmacy Services, Biospace, and OptumRx. See the full report👉 https://ow.ly/CPxf50QQBiR Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotech #FierceLifeSciencesEvents #FiercePharma #WeAreFierce
The top 10 drugs losing US exclusivity in 2024
fiercepharma.com
To view or add a comment, sign in
-
Pharma companies use integrated claims, lab, and market access data to prepare for a successful launch. In this Q&A, three clinical experts explain why: https://ow.ly/XBLT30szfx9. #Pharma #ClaimsData #LabData #MarketAccess
To view or add a comment, sign in
-
This Week in Drug Pricing: Pharma's sixth consecutive loss in court and the end of Medicare negotiation for first ten drugs. Learn more in our Week In Review: https://lnkd.in/e2ZmEFq6
To view or add a comment, sign in
-
OPQ Report Details 2023 Office Achievements in Four Strategic Priorities: The FDA’s Office of Pharmaceutical Quality (OPQ) finished out 2023 by progressing in all four of its strategic priorities: collaboration, communication, engagement, and innovation, according to its 2023 annual report. #fda #financial #lifesciences
OPQ Report Details 2023 Office Achievements in Four Strategic Priorities
fdanews.com
To view or add a comment, sign in
-
Thoughts on this? >> Faron details clinical plans for MDS drug; Cara to seek 'strategic' options >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #pharma #biotech
Faron details clinical plans for MDS drug; Cara to seek 'strategic' options
https://endpts.com
To view or add a comment, sign in
46,532 followers